Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLIN TSE:CXR OTCMKTS:ENDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLINClean Earth Acquisitions$0.01$6.76$4.54▼$11.36$234K-0.1478,528 shs5.58 million shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsENDVEndonovo Therapeutics$0.00+50.0%$0.00$0.00▼$0.00$240K-1.357.10 million shs166,770 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLINClean Earth Acquisitions-33.33%-51.01%-53.33%-32.69%-96.14%CXRConcordia International0.00%0.00%0.00%0.00%0.00%ENDVEndonovo Therapeutics+50.00%+200.00%+200.00%0.00%-66.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLINClean Earth AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/ACXRConcordia InternationalN/AN/AN/AN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLINClean Earth Acquisitions 0.00N/AN/AN/ACXRConcordia International 0.00N/AN/AN/AENDVEndonovo Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLINClean Earth AcquisitionsN/AN/AN/AN/AN/AN/ACXRConcordia InternationalC$569.62M0.00N/A5.85C$6.08 per share0.00ENDVEndonovo Therapeutics$10K36.20$0.03 per share0.01($0.08) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLINClean Earth AcquisitionsN/AN/A0.00∞N/AN/AN/AN/AN/ACXRConcordia InternationalN/AC$351.680.07N/AN/AN/AN/AN/AN/AENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLINClean Earth AcquisitionsN/AN/AN/AN/AN/ACXRConcordia InternationalN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLINClean Earth AcquisitionsN/AN/AN/ACXRConcordia International457.022.101.66ENDVEndonovo TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLINClean Earth Acquisitions26.39%CXRConcordia InternationalN/AENDVEndonovo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCLINClean Earth Acquisitions24.27%CXRConcordia InternationalN/AENDVEndonovo Therapeutics5.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLINClean Earth AcquisitionsN/A16.70 million12.65 millionNot OptionableCXRConcordia International22,50048.91 millionN/ANot OptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableCLIN, RHK, CXR, SNZ, and ENDV HeadlinesRecent News About These CompaniesEndonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, IncMarch 28, 2024 | globenewswire.comEndonovo’s SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | finance.yahoo.comEndonovo's SofPulse® to Be Featured at Innovative Pain Management SolutionsMarch 4, 2024 | globenewswire.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionDecember 4, 2023 | finance.yahoo.comEndonovo Therapeutics, Inc. (ENDV)November 21, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO)November 15, 2023 | investing.comEndonovo receives Taiwanese approval for SofPulse technologyOctober 13, 2023 | msn.comEndonovo's SofPulse® Secures Taiwan FDA ApprovalOctober 12, 2023 | finance.yahoo.comEndonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA DistributionAugust 22, 2023 | finance.yahoo.comEndonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual UpdateAugust 8, 2023 | finance.yahoo.comNew to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.June 22, 2023 | finance.yahoo.comNew to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.June 22, 2023 | finance.yahoo.comEndonovo Pending Agreement to Develop Telehealth DivisionJune 7, 2023 | finance.yahoo.comEndonovo Launches SofPulse® into the Veterans AdministrationMay 2, 2023 | finance.yahoo.comEndonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment StudiesApril 25, 2023 | finance.yahoo.comEndonovo Announces Partnership with Former NFL Dallas Cowboy Defensive LinemanApril 13, 2023 | finance.yahoo.comEndonovo Announces Partnership with Santana Lead Singer Andy VargasApril 10, 2023 | finance.yahoo.comEndonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off CompanyMarch 29, 2023 | finance.yahoo.comEndonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in TaiwanMarch 23, 2023 | finance.yahoo.comOlympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder SurgeryMarch 15, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffCLIN, RHK, CXR, SNZ, and ENDV Company DescriptionsClean Earth Acquisitions NASDAQ:CLINClean Earth Acquisitions Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring companies in the clean energy ecosystem, including carbon, hydrogen, sustainable agriculture, and renewable energy. The company was incorporated in 2021 and is based in Bee Cave, Texas.Concordia International TSE:CXRConcordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.Endonovo Therapeutics OTCMKTS:ENDV$0.0003 +0.00 (+50.00%) As of 07/10/2025 03:13 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
